A study evaluated the effect of BMTP-78 (bone metastasis targeting peptidomimetic 78), a prototype drug composed by a GRP78-binding peptide fused to the pro-apoptotic enantiomer D(KLAKLAK)2, which disrupts the mitochondrial membrane causing cell death, in a panel of human leukemia and lymphoma cell lines. This evidence concerns the gene HSPA5 and leukemia.